# A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

> **NCT04991506** · PHASE1 · COMPLETED · sponsor: **Elpiscience Biopharma, Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Solid Tumor
- Neoplasms
- Malignant Tumor

## Interventions

- **DRUG:** ES102
- **DRUG:** JS001

## Key facts

- **NCT ID:** NCT04991506
- **Lead sponsor:** Elpiscience Biopharma, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-15
- **Primary completion:** 2024-05-17
- **Final completion:** 2024-05-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04991506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04991506, "A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04991506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*